(Q42320550)

25 October 2017

Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment (English)

1 reference

epidermolysis bullosa acquisita

25 October 2017

0 references

1 reference

8

1 reference

25 October 2017

Kathrin Kalies

11

0 references

Enno Schmidt

object named as

Enno Schmidt

10

0 references

Ralf J. Ludwig

object named as

Ralf J Ludwig

13

0 references

Detlef Zillikens

12

object named as

Detlef Zillikens

1 reference

25 October 2017

1

Misa Hirose

1 reference

25 October 2017

2

Anika Kasprick

1 reference

25 October 2017

3

Foteini Beltsiou

1 reference

25 October 2017

9

Marcel F Jonkman

1 reference

25 October 2017

14

Katja Bieber

1 reference

25 October 2017

Katharina Dieckhoff Schulze

4

1 reference

25 October 2017

Franziska Sophine Schulze

5

1 reference

25 October 2017

Unni Kjsrl Samavedam

6

1 reference

25 October 2017

Jennifer E Hundt

7

1 reference

25 October 2017

language of work or name

English

0 references

publication date

20 December 2016

1 reference

25 October 2017

1 reference

25 October 2017

23

1 reference

Creative Commons Attribution 4.0 International

25 October 2017

start time

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.2119/molmed.2015.00206

0 references

cites work

Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Conditional depletion of mast cells has no impact on the severity of experimental epidermolysis bullosa acquisita.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Anti-TNF therapy: past, present and future

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Macrophage cytokines: involvement in immunity and infectious diseases

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Neutrophils recruited by chemoattractants in vivo induce microvascular plasma protein leakage through secretion of TNF

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Paradoxical effects of anti-TNF-α agents in inflammatory diseases

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Current medical treatment of ocular mucous membrane pemphigoid

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Emerging treatments for pemphigoid diseases.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Optimizing anti-TNF treatments in inflammatory bowel disease

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Epidermolysis bullosa acquisita

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Pathogenesis of epidermolysis bullosa acquisita

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Advances in pemphigus therapy.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

TNF-mediated inflammatory disease.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

TNFalpha blockade in human diseases: mechanisms and future directions

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Stimulation of G-CSF gene expression in the macrophage cell line by contact with extracellular matrix proteins and a pre-B leukaemia cell line

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Relationship of TNF to interleukins

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

An endotoxin-induced serum factor that causes necrosis of tumors

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5319204

Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease

1 December 2018

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Infliximab in the management of severe pemphigus vulgaris

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

TNFalpha and IL-6 are mediators in the blistering process of pemphigus

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2FMOLMED.2015.00206

Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27999842

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27999842

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27999842

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2119/MOLMED.2015.00206

1 reference

Dimensions Publication ID

25 October 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.2119/molmed.2015.00206

1 reference

25 October 2017

1 reference